Core Viewpoint - Haier Biomedical plans to cancel 1.4596 million repurchased shares to optimize its equity structure, reflecting its commitment to shareholder returns through a "repurchase + dividend" mechanism since its IPO in 2019 [1][2] Share Repurchase and Capital Reduction - The cancellation of shares will reduce the company's registered capital by approximately 1.46 million yuan, representing 0.46% of the total share capital, which will decrease from 318 million shares to 316 million shares [2] - This action is part of the company's ongoing efforts to fulfill its repurchase commitments and enhance its equity structure, signaling confidence in its intrinsic value [2] Financial Performance - Haier Biomedical has shown steady growth since its establishment, with revenue increasing from 1.013 billion yuan in 2019 to 2.284 billion yuan in 2024, a growth rate of 125.47%, and net profit rising from 182 million yuan to 367 million yuan, a growth rate of 101.65% [3] - However, in the first three quarters of 2025, the company faced pressure, with revenue of 1.761 billion yuan, a year-on-year decline of 1.17%, and net profit of 198 million yuan, a decrease of 35.83% [3] - The third quarter of 2025 showed signs of recovery, with revenue of 566 million yuan, a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68%, and net profit reaching 55.65 million yuan [3][4] R&D Investment and Technological Development - Over the past five years, Haier Biomedical has invested a total of 1.398 billion yuan in R&D, with annual expenditures ranging from 236 million yuan to 321 million yuan [5] - The company has established a multi-layer AI foundation and has led or participated in drafting 64 national and industry standards, with 32 recognized as internationally leading [5]

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, with significant growth in new industries contributing to revenue [1][2]. Group 1: Financial Performance - In the first half of 2025, Haier Biomedical achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1]. - The revenue share from new industries (smart medication, blood technology, laboratory solutions) increased from 38% in 2023 to 47% in 2025, a year-on-year increase of 7.27 percentage points [1][2]. Group 2: Industry Position and Innovations - The company holds over 50% market share in plasma collection solutions, maintaining its position as the leader in China [2]. - Haier Biomedical has upgraded its business model from "single equipment sales" to a comprehensive approach that includes smart devices, basic consumables, software platforms, and value-added services, enhancing customer loyalty and profitability [2]. Group 3: Research and Development - The company’s R&D investment increased by 11.61% year-on-year, accounting for 13.39% of operating revenue, focusing on AI technology integration and new product development [2]. Group 4: Market Expansion - Haier Biomedical's products are now available in over 150 countries and regions, with a 30% year-on-year increase in overseas revenue during the reporting period [3]. - The company has established localized platforms in five new countries, including Japan and Brazil, and anticipates growth in overseas markets due to the acceleration of medical infrastructure development in emerging markets [3].